Esketamine vs. sufentanil for quality of recovery after outpatient gynecological surgery: a randomized clinical trial.

Sleep health notes

Sleep health notes will be added by the Sleepatch editorial team.

中文解读

中文解读待补充：本站会优先为失眠研究、睡眠质量改善、昼夜节律等高价值睡眠研究添加中文说明。

Original abstract

<h4>Background</h4>Perioperative administration of esketamine has been reported to improve early quality of recovery (QoR). However, data on its effects in outpatient surgery are limited. This study aimed to assess the impact of esketamine on QoR in patients undergoing outpatient gynecological procedures.<h4>Methods</h4>In this investigator-initiated, double-blind, randomized clinical trial, patients aged 18-65 years scheduled for outpatient gynecological surgery under sedation were allocated to receive esketamine (0.2 mg/kg) or sufentanil (0.1 μg/kg) combined with propofol (1.5-3 mg/kg). The primary outcome was quality of recovery on postoperative day (POD) 1. Secondary outcomes included quality of recovery on POD2, sedation success rate, length of post-anesthesia care unit (PACU) stay, injection pain, postoperative pain, nausea and vomiting, fatigue, patient and clinician satisfaction, sleep quality, and anxiety and depression.<h4>Results</h4>A total of 126 patients were randomized, with 63 assigned to the esketamine group and 63 to the sufentanil group. Of these, 125 patients were included in the final analysis (62 in the esketamine group and 63 in the sufentanil group), as one patient lacked follow-up data. The mean (SD) QoR-15 score on POD1 was 137.9 (14.5) in the esketamine group and 137.8 (10.7) in the sufentanil group, with no significant difference between groups (absolute difference, 0.2; 95% CI, -4.2 to 4.6; <i>p</i> = 0.93). For secondary outcomes, the esketamine group had a longer PACU stay (median, 28.0 vs. 23.0 min; <i>p</i> < 0.001), a lower incidence of severe injection pain (22.6% vs. 50.8%; <i>p</i> = 0.002), a higher proportion of patients with pain scores ≥ 4 at 30 min postoperatively (30.6% vs. 6.3%; <i>p</i> = 0.001), and higher fatigue scores (median, 3.0 vs. 2.0; <i>p</i> = 0.01). Other secondary outcomes did not differ significantly between groups.<h4>Conclusion</h4>Among patients undergoing sedation for outpatient gynecological procedures, esketamine did not significantly improve quality of recovery on POD1 compared to sufentanil.<h4>Trial registration</h4>Chinese Clinical Trial Registry, ChiCTR2500098466.

Links and sources

• Official / arXiv page

Comments